Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.65 |
| ▸ | LCK | P06239 | 4/20 | 0.65 |
| ▸ | JAK2 | O60674 | 3/20 | 0.65 |
| ▸ | KDR | P35968 | 3/20 | 0.65 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.65 |
| ▸ | CDK1 | P06493 | 2/20 | 0.65 |
| ▸ | ROS1 | P08922 | 2/20 | 0.65 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.65 |
| ▸ | CDK2 | P24941 | 2/20 | 0.65 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.65 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.65 |
| ▸ | CLK2 | P49760 | 2/20 | 0.65 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.65 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.65 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.65 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.65 |
| ▸ | CDC7 | O00311 | 1/20 | 0.65 |
| ▸ | PLK4 | O00444 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13020470 | 0.89 | JAK2 (0.63) | SRCLCKJAK2KDRDYRK3 | |
| SCHEMBL20881666 | 0.89 | SRC (0.60) | SRCLCKJAK2KDRDYRK3 | |
| SCHEMBL3782860 | 0.89 | JAK2 (0.63) | SRCLCKJAK2KDRDYRK3 | |
| SCHEMBL4828085 | 0.87 | JAK2 (0.64) | SRCLCKJAK2KDRDYRK3 | |
| SCHEMBL17339446 | 0.87 | JAK2 (0.64) | SRCLCKJAK2KDRDYRK3 | |
| SCHEMBL4825086 | 0.86 | LCK (0.70) | SRCLCKJAK2KDRDYRK3 | |
| SCHEMBL24096723 | 0.85 | SRC (0.47) | SRCLCKJAK2KDRDYRK3 | |
| SCHEMBL24096480 | 0.85 | JAK2 (0.86) | SRCLCKJAK2KDRDYRK3 | |
| SCHEMBL20533742 | 0.82 | RET (0.68) | SRCLCKJAK2KDRDYRK3 | |
| SCHEMBL1318717 | 0.82 | SRC (0.77) | SRCLCKJAK2KDRDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317758-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-09-26 | — | — | US | disclosed |
| CN-117597346-A | NEK7 inhibitors | 哈利亚治疗公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-4320127-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| CN-116075513-A | Inhibitors of NEK7 kinase | 哈利亚治疗公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-4161933-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2022216680-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2021252488-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-7332497-B2 | As inhibitors of protein kinases | ABBOTT GMBH & CO KG (DE) | 2008-02-19 | — | — | US | disclosed |
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| EP-1379528-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1379528-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GmbH (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-01-08 | — | — | US | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002076986-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, UGT1A1, ABCB1 | SRC 2167/4885LCK 1534/4885JAK2 1515/4885 |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | SRC 651/4885LCK 1581/4885JAK2 1514/4885 |
| US-20240317758-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | SRC 1649/4885LCK 3550/4885JAK2 2736/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | SRC 1834/4885LCK 1011/4885JAK2 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.